Clinical significance of serum interleukin-6 and −174 G/C promoter polymorphism in Rheumatoid arthritis patients

Perricone, 2011, An overview on the genetic of rheumatoid arthritis: a never-ending story, Autoimmun Rev, 10, 599, 10.1016/j.autrev.2011.04.021 Nile, 2008, Methylation status of a single CpG site in the IL6 promoter is related to IL6 messenger RNA levels and rheumatoid arthritis, Arthritis Rheum, 58, 2686, 10.1002/art.23758 Marinou, 2007, Association of interleukin-6 and interleukin-10 genotypes with radiographic damage in rheumatoid arthritis is dependent on autoantibody status, Arthritis Rheum, 56, 2549, 10.1002/art.22814 Pawlik, 2005, IL-6 promoter polymorphism in patients with rheumatoid arthritis, Scand J Rheumatol, 34, 109, 10.1080/03009740510026373 Fonseca, 2009, Interleukin-6 as a key player in systemic inflammation and joint destruction, Autoimmun Rev, 8, 538, 10.1016/j.autrev.2009.01.012 Chung, 2011, The correlation between increased serum concentrations of interleukin-6 family cytokines and disease activity in rheumatoid arthritis patients, Yonsei Med J, 52, 113, 10.3349/ymj.2011.52.1.113 Fabris, 2010, Study on the possible role of the −174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis, Reumatismo, 62, 253 Pascual, 2000, IL-6 promoter polymorphisms in rheumatoid arthritis, Genes Immun, 1, 338, 10.1038/sj.gene.6363677 Marinou, 2010, A gain of function polymorphism in the interleukin 6 receptor influences RA susceptibility, Ann Rheum Dis, 69, 1191, 10.1136/ard.2008.100644 Jones, 2001, Interleukin-6, (IL-6) and the prognosis of abdominal aortic aneurysms, Circulation, 103, 2260, 10.1161/01.CIR.103.18.2260 Humphries, 2001, The interleukin-6 −174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men, Eur Heart J, 22, 2243, 10.1053/euhj.2001.2678 Mosaad, 2012, Tumor necrosis factor-α −308 G>A and interleukin-6 −174 G>C promoter polymorphisms and pemphigus, Hum Immunol, 73, 560, 10.1016/j.humimm.2012.02.001 Palomino-Morales, 2009, Interleukin-6 gene −174 promoter polymorphism is associated with endothelial dysfunction but not with disease susceptibility in patients with rheumatoid arthritis, Clin Exp Rheumatol, 27, 964 Murakami, 2011, The value of blocking IL-6 outside of rheumatoid arthritis: current perspective, Curr Opin Rheumatol, 23, 273, 10.1097/BOR.0b013e3283456797 Assier, 2010, Interleukin-6: from identification of the cytokine to development of targeted treatments, Joint Bone Spine, 77, 532, 10.1016/j.jbspin.2010.07.007 Nishimoto, 2004, Treatment of rheumatoid arthritis with humanized anti–interleukin-6 receptor antibody: a multicenter, double blind, placebo-controlled trial, Arthritis Rheum, 50, 1761, 10.1002/art.20303 Aletaha, 2010, 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative, Arthritis Rheum, 62, 2569, 10.1002/art.27584 Prevoo, 1995, Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis, Arthritis Rheum, 38, 44, 10.1002/art.1780380107 Wolfe, 2004, Development and validation of the Health Assessment Questionnaire II: a revised version of the Health Assessment Questionnaire, Arthritis Rheum, 50, 3296, 10.1002/art.20549 Larsen, 1995, How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long term studies, J Rheumatol, 22, 1974 Pola, 2002, The −174 G/C polymorphism of the interleukin-6 gene promoter and essential hypertension in an elderly Italian population, J Hum Hypertens, 16, 637, 10.1038/sj.jhh.1001462 Huang, 2007, Association of interleukin-6 and interleukin-18 gene polymorphism with rheumatoid arthritis in Guangdong Han population, Nan Fang Yi Ke Da Xue Xue Bao, 27, 1661 Brandão, 2010, Tocilizumab – a new step in rheumatoid arthritis treatment, Acta Reumatol Port, 35, 302 Lee, 2012, The association between interleukin-6 polymorphisms and rheumatoid arthritis: a meta-analysis, Inflamm Res, 61, 665, 10.1007/s00011-012-0459-1 Fabris, 2012, The CC homozygosis of the −174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis, Autoimmun Rev, 11, 315, 10.1016/j.autrev.2010.06.012 Afzal, 2011, Effect of hepatitis C virus on C-reactive protein and interleukin-6 in hemodialysis patients, Iran J Kidney Dis, 5, 182 Guzmán-Fulgencio, 2012, Plasma IL-6 and IL-9 predict the failure of interferon-α plus ribavirin therapy in HIV/HCV-coinfected patients, J Antimicrob Chemother, 67, 1238, 10.1093/jac/dkr595 Riccio, 2012, Similar serum levels of IL-6 and its soluble receptors in patients with HCV-related arthritis and rheumatoid arthritis: a pilot study, Int J Immunopathol Pharmacol, 25, 281, 10.1177/039463201202500132 Cussigh, 2011, Interleukin 6 promoter polymorphisms influence the outcome of chronic hepatitis C, Immunogenetics, 63, 33, 10.1007/s00251-010-0491-7 Van Leeuwen, 1995, Clinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study, Ann Rheum Dis, 54, 674, 10.1136/ard.54.8.674 Leffers, 2011, Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice. results from the nationwide Danish DANBIO registry, Ann Rheum Dis, 70, 1216, 10.1136/ard.2010.140129 Ceresa, 2007, Thrombopoietin is not uniquely responsible for thrombocytosis in inflammatory disorders, Platelets, 18, 579, 10.1080/09537100701593601 Buttgereit, 2011, How should impaired morning function in rheumatoid arthritis be treated?, Scand J Rheumatol Suppl, 125, 28, 10.3109/03009742.2011.566438 Sierakowski, 2011, Morning symptoms in rheumatoid arthritis: a defining characteristic and marker of active disease, Scand J Rheumatol Suppl, 125, 1, 10.3109/03009742.2011.566433 Burmester, 2011, Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA), Ann Rheum Dis, 70, 755, 10.1136/ard.2010.139725 Ceccarelli, 2011, Transforming growth factor-beta 869C/T and interleukin-6 −174G/C polymorphisms relate to the severity and progression of bone erosive damage detected by ultrasound in rheumatoid arthritis, Arthritis Res Ther, 13, R111, 10.1186/ar3396 Pawlik, 2005, The influence of IL-6 polymorphism on efficacy of treatment of rheumatoid arthritis patients with methotrexate and prednisone, Pol Arch Med Wewn, 114, 843